Pharmaceutical Benefits Advisory Committee (PBAC) - Enhertu for HER2-low Metastatic Breast Cancer
The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the drug Enhertu (trastuzumab deruxtecan) for people with HER2-low metastatic breast cancer (MBC) to be subsidised on the Pharmaceutical Benefits Scheme (PBS). We now call on the Australian Government to work with the pharmaceutical company to list Enhertu on the PBS as quickly as possible, to save people thousands of dollars. BCNA also urges AstraZeneca to reduce the cost of its Patient Access Program for Enhertu whilst we await PBS listing, to ensure as many people as possible can access this life-prolonging dug. Sarah (pictured), who was diagnosed with metastatic breast cancer in 2017 at the age of 41, has spent over $200,000 on Enhertu privately until she recently became eligible for the patient access program. “[Enhertu means that] my children will have a mum who loves them unconditionally – for longer. My husband will have a wife – the love of his life – for longer.” If you have any questions about Enhertu we encourage you to speak to your treating team. Read further details via the link https://www.bcna.org.au/media-releases/enhertu-recommended-for-pbs-subsidy-but-it-is-not-time-to-celebrate/
